VN April 2020

Vetnews | April 2020 27 it has the capability to cross-link large antigens such as viruses and bacteria, trapping them in the mucous layer to be removed with the mucous. In this way infection and colonisation of viruses and bacteria are prevented. 1 This high efficacy of IgA, alongwith other innate immune responses in the mucosa, is why there is a lot of research going into mucosal vaccines. As an additional layer of defence to humoral immunity, mucosal vaccination can give added protection at an additional level against the same disease, thus enhancing overall immunity and disease resistance. 2 A common example in human vaccines that most people are familiar with, is the Polio vaccine that is administered via drops in the mouth, to induce mucosal immunity in the GALT. 2 In addition to inducing mucosal immunity and IgA production, recent studies have shown that certain mucosal vaccines can also have a beneficial effect on systemic immunity and IgG production when used in conjunction with a systemic vaccine. 3 Cortese VS et al . published an article in EC Veterinary Science in January 2020, that clearly illustrates the value of strategically using intra-nasal vaccination in cattle, for the benefit of a PRIME BOOST effect. 3 A lot of vaccines used today require the use of a booster dose to gain an optimal immune response. This booster doses, however, are with the same homologous vaccine. Prime boosting specifically refers to priming and boosting with heterologous vaccines – i.e. vaccines containing the same antigens administered through different delivery methods. 3 The study comprised of 400 new-born Angus-based calves, that were randomly assigned to eight different treatment groups, each receiving a different combination (and chronology) of vaccines at birth; day 60, day 210, day 240 and day 280. A control groupwas also included. The vaccines that was included in the study comprised of: 1. An intra-nasal vaccine (IN) containing modified live temperature sensitive (MLV-TS) bovine herpes virus-1 (BHV-1); bovine respiratory syncytial virus (BRSV) and parainfluenza-3 virus (PI3). 2. A systemic vaccine with MLV bovine viral diarrhoea virus (BVDV) types 1- and 2 in combination with a Mannheimia haemolytica (Mh) inactivated leukotoxoid. 3. A systemic vaccine with an MLV combination of BVDV types 1- and 2; BHV-1; BRSV and PI3 virus. At the days of vaccination nasal swabs and serum were collected from all the test subjects and analysed for IgG- and IgA antibody levels for BHV-1. Care was taken to ensure that no evidence of wild BHV-1 exposure was observed in the control group throughout the study. A significant finding in this study was the fact that systemic IgG titres for BHV-1 were significantly higher on day 240 and day 280 in calves that received either one or two intranasal (IN) vaccines BEFORE systemic vaccination. This clearly illustrated the prime boost effect that can be attained when an initial IN vaccination is administered early in a calf’s life, followed up with a systemic vaccination. This is exciting work and opens up the door for more studies to be done in this regard, it reveals valuable insights into prime boost technologies in calves and proves that IN vaccination has systemic immune benefits that can be tapped into, in addition to local mucosal immunity. References 1. Kindt TJ, Goldsby RA, Osborne BA. Kuby.2007. Immunology Sixth Edition. WH Freeman and Company: 41 Madison Avenue, New York, NY 10010 p 46-48, 99-100 2. Data on file. Zoetis Internal Learning Guide. 3. CorteseVS, Seeger JT, Trejo C, Short TH. 2020. Antibody responses to BHV-1 vaccination in neonatal calves and in prime-boost programs. EC Veterinary Science 5.2: p 1-11. v Regulars I Zoetis pages Figure 2: Structure and formation of secretory IgA Image credit: Kindt TJ, Goldsby RA, Osborne BA. 2007. Kuby Immunology Sixth Edition. WH Freeman and Company: 41 Madison Avenue, New York, NY 10010. p 46-48, 99-100

RkJQdWJsaXNoZXIy OTc5MDU=